FINWIRES · TerminalLIVE
FINWIRES

C21 Investments Q4 Loss From Continuing Operations Narrows

By

C21 Investments (CXXI.CN) overnight Thursday reported a narrowed loss from continuing operations in the fourth quarter even as revenue decreased year-over-year.

For the three months ended March 31, 2026, the company reported loss from continuing operations of US$1.4 million or US$0.01 loss per basic and diluted common share, compared with $1.5 million or $0.01 loss per share, a year earlier.

Revenue decreased to US$7.5 million compared with $8.1 million, a year-ago, due to seasonality and price compression, it said.

Shares of the company closed down 10% to $0.385 on Thursday on the Canadian Securities Exchange.

Related Articles

Mining & Metals

Lundin Gold Distributes 50.5-Million LunR Royalties Shares Through Dividend

Lundin Gold (LUG.TO) after trade Thursday said it completed the distribution of 50.5 million shares of LunR Royalties (LUNR.V) to its shareholders through a dividend in kind.The distribution was made on Thursday to shareholders of record as of June 4. The shares were acquired by Lundin Gold on May 28 as part of a silver stream agreement with LunR Royalties. Under a separate agreement signed in April, Lundin Gold committed to distributing these shares directly to its shareholders, the company said.Before the distribution, Lundin Gold owned about 41.8% of LunR's outstanding shares. Through the transaction, the company distributed its entire LunR stake to shareholders and no longer holds any shares in LunR, according to the statement."As a result, Lundin Gold is no longer subject to early warning reporting requirements in respect of LunR. Lundin Gold has no current intention to acquire additional securities of LunR," the company added.

$LUG.TO$LUNR.V
Mining & Metals

ZYUS Life Sciences Announces Strategic Realignment to Prioritize Drug Development

ZYUS Life Sciences (ZYUS.V) on Thursday announced a strategic realignment of its corporate structure and leadership as the clinical-stage drug developer sharpens its focus on core clinical development programs.The company said it will discontinue its international business development activities, a move aimed at reducing overhead costs and redirecting resources toward its non-opioid pain management drug development pipeline. As part of the initiative, ZYUS will also begin a formal wind-down of its international legal entities.In connection with the restructuring, Keith Carpenter will step down as chief strategy and investment officer, effective June 11."This realignment reflects our commitment to focusing resources on the areas that we believe will create the greatest value for patients and shareholders," said chief executive Brent Zettl.The company's shares last traded May 8 on the TSX Venture Exchange, after being halted by regulators until the company provides annual audited financial statements for 2025.

$ZYUS.V
Mining & Metals

Market Chatter: H&R REIT in Talks About a Potential Sale to Blackstone, Bloomberg Reports

H&R Real Estate Investment Trust (HR-UN.TO) is in discussions with Blackstone about a potential sale of the REIT, Bloomberg News reported Thursday.Citing "people with knowledge of the matter", the news service said the talks follow on negotiations last year involving H&R, Blackstone, TPG Inc. and Crestpoint Real Estate Investments that fell apart.The report said hedge fund K2 & Associates Investment Management is pushing the REIT to explore a sale.Bloomberg said Blackstone declined to comment on the potential acquisition, while H&R didn't reply to a request for comment.H&R units closed up C$0.90, or 8.6%, to $11.39 on the Toronto Stock Exchange.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$HR-UN.TO